Cutler Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $893K | Sell |
6,900
-11,634
| -63% | -$1.43M | 0.29% | 77 |
|
|
2023
Q4 | $1.79M | Sell |
18,534
-5,481
| -23% | -$526K | 0.16% | 123 |
|
|
2023
Q3 | $2.91M | Buy |
24,015
+2,524
| +12% | +$285K | 0.3% | 63 |
|
|
2023
Q2 | $2.46M | Buy |
21,491
+30
| +0.1% | +$3.87K | 0.34% | 58 |
|
|
2023
Q1 | $2.96M | Buy |
21,461
+7,761
| +57% | +$1.01M | 0.31% | 71 |
|
|
2022
Q4 | $1.77M | Buy |
13,700
+1,800
| +15% | +$209K | 0.15% | 144 |
|
|
2022
Q3 | $1.31M | Sell |
11,900
-5,985
| -33% | -$603K | 0.09% | 228 |
|
|
2022
Q2 | $1.34M | Buy |
17,885
+7,735
| +76% | +$569K | 0.09% | 263 |
|
|
2022
Q1 | $792K | Sell |
10,150
-22,680
| -69% | -$1.74M | 0.04% | 474 |
|
|
2021
Q4 | $2.96M | Buy |
32,830
+7,330
| +29% | +$627K | 0.12% | 173 |
|
|
2021
Q3 | $2.36M | Buy |
25,500
+21,600
| +554% | +$1.66M | 0.11% | 208 |
|
|
2021
Q2 | $303K | Sell |
3,900
-4,664
| -54% | -$354K | 0.01% | 1053 |
|
|
2021
Q1 | $638K | Buy |
+8,564
| New | +$790K | 0.03% | 626 |
|
|
2020
Q4 | – | Sell |
-2,300
| Closed | -$341K | – | 5456 |
|
|
2020
Q3 | $322K | Buy |
+2,300
| New | +$350K | 0.02% | 696 |
|
|
2020
Q2 | – | Sell |
-5,001
| Closed | -$681K | – | 4846 |
|
|
2020
Q1 | $489K | Sell |
5,001
-6,899
| -58% | -$789K | 0.03% | 557 |
|
|
2019
Q4 | $1.53M | Buy |
11,900
+2,100
| +21% | +$212K | 0.09% | 191 |
|
|
2019
Q3 | $738K | Sell |
9,800
-5,104
| -34% | -$603K | 0.07% | 254 |
|
|
2019
Q2 | $2.26M | Buy |
14,904
+8,804
| +144% | +$1.07M | 0.21% | 79 |
|
|
2019
Q1 | $727K | Sell |
6,100
-903
| -13% | -$116K | 0.08% | 239 |
|
|
2018
Q4 | $764K | Buy |
7,003
+6,700
| +2,211% | +$838K | 0.07% | 240 |
|
|
2018
Q3 | $48K | Sell |
303
-18,978
| -98% | -$2.59M | ﹤0.01% | 1636 |
|
|
2018
Q2 | $2.55M | Buy |
19,281
+16,926
| +719% | +$1.6M | 0.2% | 93 |
|
|
2018
Q1 | $174K | Buy |
2,355
+2,011
| +585% | +$134K | 0.02% | 897 |
|
|
2017
Q4 | $19K | Sell |
344
-6,592
| -95% | -$349K | ﹤0.01% | 2611 |
|
|
2017
Q3 | $314K | Buy |
6,936
+783
| +13% | +$31.3K | 0.01% | 894 |
|
|
2017
Q2 | $207K | Buy |
6,153
+2,298
| +60% | +$74.8K | 0.01% | 1250 |
|
|
2017
Q1 | $114K | Sell |
3,855
-110,040
| -97% | -$3.41M | ﹤0.01% | 1619 |
|
|
2016
Q4 | $3.12M | Buy |
113,895
+49,885
| +78% | +$2M | 0.11% | 129 |
|
|
2016
Q3 | $3.93M | Sell |
64,010
-91,192
| -59% | -$2.76M | 0.18% | 87 |
|
|
2016
Q2 | $2.96M | Buy |
155,202
+59,021
| +61% | +$1.09M | 0.15% | 103 |
|
|
2016
Q1 | $1.88M | Buy |
96,181
+54,107
| +129% | +$945K | 0.12% | 128 |
|
|
2015
Q4 | $1.62M | Buy |
+42,074
| New | +$1.36M | 0.09% | 209 |
|
Other funds holding SRPT
ACA
FCM
Cutler Group's SRPT Position: Q1 2024 in Review
Cutler Group reduced its Sarepta Therapeutics (SRPT) stake by 63% in Q1 2024, selling an estimated $1.43M and leaving 6,900 shares worth $893K. The position accounts for 0.29% of the portfolio, ranked #77.
Cutler Group first reported a position in SRPT in Q4 2015 and has held it in 32 quarters since. The position peaked at $3.93M in Q3 2016. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.
- Cutler Group held 6,900 shares of Sarepta Therapeutics worth $893K as of Q1 2024.
- Cutler Group sold 11,634 Sarepta Therapeutics shares in Q1 2024, an estimated $1.43M.
- Sarepta Therapeutics made up 0.29% of Cutler Group's portfolio in Q1 2024, its #77 holding.
- Cutler Group first reported a position in Sarepta Therapeutics in Q4 2015 and has held it in 32 quarters since.
- Cutler Group's Sarepta Therapeutics position peaked at $3.93M in Q3 2016.
- 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.